CoChat

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease

Open access

The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index, and 2 are not checked yet; 10 of the 45 sources its claims cite were checked for support.

Abstract

OBJECTIVE: To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroinflammation, and cerebrovascular changes and study their associations with the core biomarkers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging correlates, and clinical disease progression over time. METHODS: The study included cognitively unimpaired elderly (n = 508), patients with mild cognitive impairment (MCI, n = 256), and patients with AD dementia (n = 57) from the longitudinal Swedish BioFINDER cohort. CSF samples were analyzed for YKL-40, interleukin (IL)-6, IL-7, IL-8, IL-15, IP-10, monocyte chemoattractant protein 1, intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), placental growth factor, and fms-related tyrosine kinase 1 (Flt-1). MRI data were available from 677 study participants. Longitudinal clinical assessments were conducted in control individuals and patients with MCI (mean follow-up 3 years, range 1-6 years). RESULTS: CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased during the preclinical, prodromal, and dementia stages of AD. High levels of these biomarkers were associated with increased CSF levels of total tau, with the associations, especially for YKL-40, being stronger in Aβ-positive individuals. The results were similar for associations between phosphorylated tau and YKL-40, ICAM-1, and VCAM-1. High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions) and with subsequent cognitive deterioration in patients without dementia as measured with Mini-Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40, ICAM-1, VCAM-1 and IL-15). Finally, higher levels of CSF YKL-40, ICAM-1, and Flt-1 increased risk of development of AD dementia in patients without dementia. CONCLUSIONS: Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression.

Verified 2026-10-05 · 2 references not checked yet

Overview

CoChat Summary

TL;DR

In the Swedish BioFINDER cohort, CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were elevated in preclinical, prodromal, and dementia stages of Alzheimer disease and were associated with tau pathology, cortical thinning, cognitive decline, and progression to AD dementia. The authors conclude that neuroinflammation and cerebrovascular dysfunction are early events in AD that may contribute to disease progression.

Key findings

  • Pathologic Aβ status was associated with higher CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 (all p < 0.001) in both control and MCI groups; these biomarkers were increased in control–Aβ+, MCI–Aβ+, and AD dementia groups compared with control–Aβ−, but not in MCI–Aβ−.
  • Higher CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were associated with higher t-tau and p-tau; interactions with Aβ status were significant for t-tau (YKL-40 p < 0.001; ICAM-1 p = 0.040; VCAM-1 p = 0.002; IL-15 p = 0.043; Flt-1 p = 0.001) and for p-tau with YKL-40 (p < 0.001), ICAM-1 (p = 0.024), and VCAM-1 (p = 0.011).
  • Higher biomarker levels were associated with cortical thinning primarily in precuneus and superior parietal regions; YKL-40 was associated with reduced left and right caudate and left amygdala volumes (β = −0.092, p = 0.036; β = −0.124, p < 0.001; β = −0.102, p = 0.030; false discovery rate–adjusted p values).
  • In participants without dementia, higher YKL-40 was associated with lower baseline MMSE and faster MMSE decline; YKL-40, VCAM-1, and IL-15 were associated with higher baseline CDR-SB, and YKL-40, ICAM-1, VCAM-1, and IL-15 with faster CDR-SB increase. Among 728 followed participants, 115 (15.8%) progressed to AD dementia; highest tertiles of YKL-40 (p = 0.005), ICAM-1 (p = 0.001), and Flt-1 (p = 0.007) were associated with increased risk.

Methods

  • Longitudinal Swedish BioFINDER cohort: 508 cognitively unimpaired elderly (315 cognitively normal plus 193 with subjective cognitive decline), 256 patients with MCI, and 57 patients with AD dementia; MRI data were available for 677 participants after quality control; longitudinal clinical assessments in controls and MCI had mean follow-up 3 years (range 1–6 years).
  • CSF was analyzed for 11 neuroinflammatory and cerebrovascular biomarkers (YKL-40, IL-6, IL-7, IL-8, IL-15, IP-10, MCP-1, ICAM-1, VCAM-1, PlGF, Flt-1) using Mesoscale Discovery immunoassay and ELISA for YKL-40, Aβ42, Aβ40, t-tau, and p-tau; Aβ status was defined by CSF Aβ42/Aβ40 ratio cutoff ≤0.1.
  • Analyses included ANOVA/GLM with Bonferroni correction, linear regression, linear mixed-effects models for longitudinal MMSE and CDR-SB, Cox proportional hazards models for time to AD dementia, and voxel-wise/region-of-interest MRI analyses with false discovery rate correction at q = 0.05; models adjusted for age, sex, and APOE genotype, with anti-inflammatory medications considered in initial analyses.

Limitations

  • The paper does not include a formal limitations section. The authors note considerable overlap in CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 between groups, suggesting AD may be accompanied by neuroinflammation and cerebrovascular dysfunction in a subpopulation of patients, and state that future longitudinal assessments of biomarker levels are warranted.
  • Evident from the text: the study is observational, and the reported associations cannot establish causality; the authors describe the processes as possibly contributing to tau pathology, neurodegeneration, atrophy, and AD risk.
  • Evident from the text: several analyses and data are reported as available from Dryad rather than fully in the main paper, and the cohort is from the Swedish BioFINDER study with follow-up averaging 3 years (range 1–6 years), which may limit generalizability and long-term inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000006082

Cites

46 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CSF biomarkers of neuroinflammation and cerebrovascular changes in diagnostic groups CSF levels of YKL-40 (A), intercellular adhesion molecule 1 (ICAM-1) (B), vascular adhesion molecule 1 (VCAM-1) (C), interleukin-15 (IL-15) (D), and fms-related tyrosine kinase 1 (Flt-1) (E) in cognitively unimpaired controls and patients with mild cognitive impairment (MCI) with normal (Ctrl–β-amyloid (Aβ)−, MCI–Aβ−, Aβ42/Aβ40 >0.1) and pathologic (Ctrl–Aβ+, MCI–Aβ+, Aβ42/Aβ40 ≤0.1) CSF Aβ status and patients with Alzheimer disease (AD) dementia. For comparison, CSF levels of total tau in the same diagnostic groups are shown in (F). The dotted lines indicate median levels in the Ctrl-Aβ− group. p Values are from one-way analysis of variance; statistical significance was set to p < 0.0071 (0.05/7) to account for Bonferroni correction. The significant findings were very similar when adjusting for the covariates (age, sex, APOE ε4 genotype, and anti-inflammatory medications), with the exception of ICAM-1, for which there were no differences between the groups with pathologic CSF Aβ status (Ctrl–Aβ+, MCI–Aβ+, and AD dementia).
Figure 1 CSF biomarkers of neuroinflammation and cerebrovascular changes in diagnostic groups CSF levels of YKL-40 (A), intercellular adhesion molecule 1 (ICAM-1) (B), vascular adhesion molecule 1 (VCAM-1) (C), interleukin-15 (IL-15) (D), and fms-related tyrosine kinase 1 (Flt-1) (E) in cognitively unimpaired controls and patients with mild cognitive impairment (MCI) with normal (Ctrl–β-amyloid (Aβ)−, MCI–Aβ−, Aβ42/Aβ40 >0.1) and pathologic (Ctrl–Aβ+, MCI–Aβ+, Aβ42/Aβ40 ≤0.1) CSF Aβ status and patients with Alzheimer disease (AD) dementia. For comparison, CSF levels of total tau in the same diagnostic groups are shown in (F). The dotted lines indicate median levels in the Ctrl-Aβ− group. p Values are from one-way analysis of variance; statistical significance was set to p < 0.0071 (0.05/7) to account for Bonferroni correction. The significant findings were very similar when adjusting for the covariates (age, sex, APOE ε4 genotype, and anti-inflammatory medications), with the exception of ICAM-1, for which there were no differences between the groups with pathologic CSF Aβ status (Ctrl–Aβ+, MCI–Aβ+, and AD dementia).CC BY · PubMed Central
Figure 2 CSF biomarkers of neuroinflammation and cerebrovascular changes, CSF tau, and cortical atrophy (A, B) Association between CSF YKL-40 and total tau (t-tau) and CSF YKL-40 and phosphorylated tau (p-tau), respectively, in study participants with normal (β-amyloid [Aβ]−) and pathologic (Aβ+) CSF status. Unstandardized B coefficients and p values for slopes are from linear regression models. The results were very similar when adjusting for the covariates (age, sex, APOE ε4 genotype, and anti-inflammatory medications). (C) Associations between YKL-40 and cortical thickness. Voxel-wise regression analysis corrected for age, sex, and APOE ε4.
Figure 2 CSF biomarkers of neuroinflammation and cerebrovascular changes, CSF tau, and cortical atrophy (A, B) Association between CSF YKL-40 and total tau (t-tau) and CSF YKL-40 and phosphorylated tau (p-tau), respectively, in study participants with normal (β-amyloid [Aβ]−) and pathologic (Aβ+) CSF status. Unstandardized B coefficients and p values for slopes are from linear regression models. The results were very similar when adjusting for the covariates (age, sex, APOE ε4 genotype, and anti-inflammatory medications). (C) Associations between YKL-40 and cortical thickness. Voxel-wise regression analysis corrected for age, sex, and APOE ε4.CC BY · PubMed Central
Figure 3 CSF biomarkers of neuroinflammation and cerebrovascular changes and progression to Alzheimer disease (AD) Kaplan-Meier curves of progression from cognitively normal and mild cognitive impairment (MCI) to AD for tertiles of YKL-40 (A), intercellular adhesion molecule 1 (ICAM-1) (B), and fms-related tyrosine kinase 1 (Flt-1) (C).
Figure 3 CSF biomarkers of neuroinflammation and cerebrovascular changes and progression to Alzheimer disease (AD) Kaplan-Meier curves of progression from cognitively normal and mild cognitive impairment (MCI) to AD for tertiles of YKL-40 (A), intercellular adhesion molecule 1 (ICAM-1) (B), and fms-related tyrosine kinase 1 (Flt-1) (C).CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 0 Not valid · 20 Not checked · 72 Own results and interpretations

49 more claims

Create a free account to see all 100 claims and to verify the 35 references still open.

See all claims — free account
  • Probably not a substantial claim. 33
  • It may state two separate claims as one. 29

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Team RC. R: language and environment for statistical computing. In: R Foundation for Statistical Computing. Vienna, Austria: 2014. Available at: r-project.org/. Accessed September 17, 2016.

Cited by

See all 383

Metadata

Authors
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O.
Affiliations
Lund University (SE)
Corresponding author
Hansson, Oskar
Venue
Neurology
Published
2018-08-28
Volume
91
Issue
9
Pages
e867-e877
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2883326166
Cited by
359
References
48
Citations by year
2026: 29 · 2025: 53 · 2024: 65 · 2023: 40 · 2022: 40 · 2021: 60 · 2020: 46 · 2019: 23 · 2018: 2
FWCI
25.77
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Australian Government
  • Marcus Foundation
  • Vetenskapsrådet
  • Marcus och Amalia Wallenbergs minnesfond
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, cerebrospinal fluid biomarkers, neuroinflammation, cerebrovascular dysfunction, YKL-40, ICAM-1, VCAM-1, IL-15, Flt-1, microglial activation, astrocyte activation, amyloid-beta, tau protein, mild cognitive impairment, cortical thinning, cognitive decline, disease progression
MeSH terms
Chitinase-3-Like Protein 1, Placenta Growth Factor, Aged, Aged, 80 and over, Cerebrovascular Disorders, Encephalitis, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Biomarkers, Cytokines, Amyloid beta-Peptides, tau Proteins, Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, Vascular Endothelial Growth Factor Receptor-1, Apolipoprotein E4, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000006082
The paper
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018). CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000006082

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.